CancerDrs

Lung Cancer clinical trials in Ohio

76 actively recruiting lung cancer trials at 63 sites across Ohio.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Ohio:
  • Aultman Alliance Community Hospital — Alliance, Ohio
  • OhioHealth O'Bleness Hospital — Athens, Ohio
  • UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Ohio:
  • Cleveland Clinic Akron General — Akron, Ohio
  • Aultman Alliance Community Hospital — Alliance, Ohio
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Saint Elizabeth Boardman Hospital — Boardman, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Ohio:
  • UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Saint Elizabeth Boardman Hospital — Boardman, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Ohio:
  • Cleveland Clinic Akron General — Akron, Ohio
  • UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
  • Cleveland Clinic Mercy Hospital — Canton, Ohio
  • Aultman Health Foundation — Canton, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Ohio:
  • Cleveland Clinic Akron General — Akron, Ohio
  • Aultman Health Foundation — Canton, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
  • University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
  • MetroHealth Medical Center — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Ohio:
  • UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Aultman Health Foundation — Canton, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Ohio:
  • UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
  • Case Western Reserve University — Cleveland, Ohio
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Ohio:
  • Children's Hospital Medical Center of Akron — Akron, Ohio
  • Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
  • Rainbow Babies and Childrens Hospital — Cleveland, Ohio
  • Cleveland Clinic Foundation — Cleveland, Ohio
  • Nationwide Children's Hospital — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Ohio:
  • University Hospitals Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • Oncology Hematology Care Inc — Cincinnati, Ohio
  • Oncology Hematology Care — Cincinnati, Ohio
  • Oncology Hematology Care Inc — Cincinnati, Ohio
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Ohio:
  • Clinical Study Sites — Cincinnati, Ohio
  • Clinical Study Site — Cleveland, Ohio
  • Clinical Study Sites — Columbus, Ohio
  • Clinical Study Site — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…

Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in Ohio:
  • Mercy Health - Perrysburg Cancer Center — Perrysburg, Ohio
  • Mercy Health - St. Anne Cancer Center — Toledo, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Ohio:
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Ohio:
  • Summa Health ( Site 4011) — Akron, Ohio
  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0028) — Cincinnati, Ohio
  • University Hospitals Cleveland Medical Center ( Site 0023) — Cleveland, Ohio
  • OSU Brain and Spine Hospital ( Site 0016) — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Ohio:
  • Research Site — Cincinnati, Ohio
  • Research Site — Columbus, Ohio
  • Research Site — Maumee, Ohio
  • Research Site — Toledo, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Ohio:
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Ohio:
  • University of Cincinnati Medical Center ( Site 0119) — Cincinnati, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Ohio:
  • Genesis Cancer Care Center /ID# 239190 — Zanesville, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Ohio:
  • Local Institution - 0163 — Cleveland, Ohio
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Ohio:
  • Local Institution - 0383 — Cincinnati, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Ohio:
  • Gabrail Cancer Center Research — Canton, Ohio
  • The Christ Hospital Cancer Center — Cincinnati, Ohio
  • University of Cincinnati Medical Center — Cincinnati, Ohio
  • The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion — Cleveland, Ohio
  • Cleveland Clinic — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Ohio:
  • ProMedica Flower Hospital — Sylvania, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in Ohio:
  • Research Site — Maumee, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Ohio:
  • Oncology Hematology Care - Fairfield /ID# 280641 — Fairfield, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…

Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in Ohio:
  • University of Cincinnati Cancer Center — Cincinnati, Ohio
  • The Ohio State University — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…

Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Ohio:
  • University of Cincinnati Medical Center — Cincinnati, Ohio
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
View on ClinicalTrials.gov →

Showing 25 of 76 trials with sites in Ohio. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17